Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.62 |
| ▸ | HPGD | P15428 | 2/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | HTT | P42858 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23116936 | 0.86 | NR4A3 (0.66) | ALDH1A1HPGDSMN1; SMN2KDM4ENR4A3 | |
| SCHEMBL13887595 | 0.85 | NR4A3 (0.72) | ALDH1A1HPGDSMN1; SMN2HTTRAB9A | |
| SCHEMBL21366475 | 0.84 | RIPK2 (0.55) | ALDH1A1HPGDSMN1; SMN2KDM4ENR4A3 | |
| SCHEMBL21357581 | 0.83 | ALDH1A1 (0.68) | ALDH1A1HPGDSMN1; SMN2HTTRAB9A | |
| SCHEMBL2326321 | 0.83 | ALDH1A1 (0.68) | ALDH1A1HPGDSMN1; SMN2HTTRAB9A | |
| SCHEMBL18134663 | 0.82 | ALDH1A1 (0.64) | ALDH1A1HPGDSMN1; SMN2HTTRAB9A | |
| SCHEMBL18733483 | 0.81 | ALDH1A1 (0.65) | ALDH1A1HPGDSMN1; SMN2HTTRAB9A | |
| SCHEMBL1065124 | 0.79 | ALDH1A1 (0.75) | ALDH1A1HPGDSMN1; SMN2HTTRAB9A | |
| SCHEMBL798337 | 0.78 | ALDH1A1 (0.73) | ALDH1A1HPGDSMN1; SMN2HTTRAB9A | |
| SCHEMBL23116878 | 0.77 | ALDH1A1 (0.55) | ALDH1A1HPGDSMN1; SMN2HTTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11597702-B2 | Substituted pyrazoles FFA4/GPR120 receptor agonists | GOLGI NEUROSCIENCES S.R.L. (IT) | 2023-03-07 | — | — | US | disclosed |
| US-11597702-B2 | Substituted pyrazoles FFA4/GPR120 receptor agonists | GOLGI NEUROSCIENCES S.R.L. (IT) | 2023-03-07 | — | — | US | disclosed |
| US-20210087148-A1 | SUBSTITUTED PYRAZOLES FFA4/GPR120 RECEPTOR AGONISTS | GOLGI NEUROSCIENCES S.R.L. (IT) | 2021-03-25 | — | — | US | disclosed |
| US-20210087148-A1 | SUBSTITUTED PYRAZOLES FFA4/GPR120 RECEPTOR AGONISTS | GOLGI NEUROSCIENCES S.R.L. (IT) | 2021-03-25 | — | — | US | disclosed |
| CN-111868035-A | Substituted pyrazole FFA4/GPR120 receptor agonists | 阿克萨姆股份公司 | 2020-10-30 | — | — | CN | disclosed |
| WO-2019175152-A1 | SUBSTITUTED PYRAZOLES FFA4/GPR120 RECEPTOR AGONISTS | AXXAM S.P.A. (IT) | 2019-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210087148-A1 | SUBSTITUTED PYRAZOLES FFA4/GPR120 RECEPTOR AGONISTS | FFAR4, FFAR3, FFAR1 | ALDH1A1 1740/4885HPGD 2093/4885SMN1; SMN2 2927/4885 |
| US-11597702-B2 | Substituted pyrazoles FFA4/GPR120 receptor agonists | FFAR4, FFAR3, FFAR1 | ALDH1A1 1740/4885HPGD 2093/4885SMN1; SMN2 2927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.